Vertex Pharmaceuticals: I'm Downgrading To Hold On Drug Pricing, Pipeline Concerns

Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Assessing Vertex Pharmaceuticals: Insights From 15 Financial Analysts

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...

Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership

Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here ...
Zacks Investment Research on MSN

Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...
Zacks Investment Research on MSN

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...
The Bakersfield Californian

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball world champion Jayson Tatum to raise awareness of JOURNAVX ® (su ...